Chester County News and Community Website
KING OF PRUSSIA, PA — CSL plans to seek approval to expand ANDEMBRY to children ages 2 through 11 after a Phase 3b study found most participants remained free of …
CSL Plans Pediatric ANDEMBRY Filing After Phase 3b Data Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) has received authorization from the Abu Dhabi Department of Health to begin a Phase 2a clinical trial of its investigational therapy Teverelix …
ICYMI: Medicus Pharma Wins UAE Trial Authorization for Endometriosis Study Read More
DOYLESTOWN, PA — Aprea Therapeutics Inc. (Nasdaq: APRE) is expanding enrollment and broadening the clinical development strategy for its investigational WEE1 inhibitor APR-1051 as the company advances a Phase 1 …
Aprea Expands APR-1051 Trial as Enrollment Accelerates Read More
MALVERN, PA — The U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy designation to Ocugen Inc.’s experimental OCU410 gene therapy for geographic atrophy, giving the blindness treatment access …
FDA Gives Ocugen Gene Therapy Expedited Regulatory Status Read More PHILADELPHIA, PA — Medicus Pharma Ltd. received FDA clearance to begin a registrational Phase 2b trial of its SkinJect microneedle patch in patients with Gorlin Syndrome, advancing the treatment toward …
ICYMI: FDA Clears Medicus to Begin Gorlin Syndrome SkinJect Trial Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) received authorization from Abu Dhabi health regulators to proceed with a Phase 2a trial of Teverelix in women with symptomatic endometriosis, advancing …
Medicus Wins UAE Clearance for Genomics-Guided Drug Trial Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) received U.S. Food and Drug Administration authorization to begin a registrational Phase 2b study of its SkinJect treatment in patients with Gorlin …
FDA Clears Medicus to Start Gorlin Syndrome Drug Study Read More
WILMINGTON, DE — Incyte (Nasdaq: INCY) reported that its experimental drug latarcibart reduced the median annualized bleeding rate by 81% in a 16-patient Phase 1/2 study, supporting the company’s decision …
Incyte Drug Cuts Bleeding Rate 81% in Early VWD Study Read More
MALVERN, PA — MAXONA Pharmaceuticals has received U.S. Food and Drug Administration clearance to begin a Phase 2 clinical trial of its investigational non-opioid pain therapy, advancing the company’s effort …
FDA Clears MAXONA Pain Drug for Phase 2 Trial Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) is moving toward activation of a redesigned Phase 2 Teverelix trial after receiving FDA feedback and central ethics approval, cutting planned enrollment …
ICYMI: Medicus Advances Leaner Teverelix Trial After FDA Review Read More